Boehringer Ingelheim said it will seek approval for survodutide for obesity next year after trial results showed no increased cardiovascular event risk versus expectations. The company framed the Phase 3 cardiovascular safety outcome as it eyes additional market share in a crowded anti-obesity class. The move highlights how obesity developers are increasingly competing on both efficacy and cardiovascular safety datasets, with regulators and payers pressuring manufacturers to demonstrate event risk mitigation rather than relying on surrogate endpoints.